XML 83 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Additional Information (Detail) - Licensing Agreement [Member] - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 31, 2021
Jun. 30, 2021
Oasmia [Member]    
Statement [line items]    
Upfront payment received   $ 4,000
Simcere Pharmaceutical Group Limited [Member]    
Statement [line items]    
Upfront payment received $ 11,000  
Upfront payment received in cash 7,000  
Upfront payment received in shares $ 4,000  
Premium on investment percentage 20.00%  
Oasmia And Simcere Pharmaceutical Group [Member]    
Statement [line items]    
Revenue recognized out of consideration received from customers during the period   0
Oasmia Pharmceutical AB And Sincere Pharmaceuticals Group Limited [Member]    
Statement [line items]    
Revenue from performance obligations satisfied or partially satisfied in previous periods   11,000
Commercial Milestone [Member] | Oasmia [Member]    
Statement [line items]    
Contingent milestone payment receivable   42,000
Commercial Milestone [Member] | Simcere Pharmaceutical Group Limited [Member]    
Statement [line items]    
Contingent milestone payment receivable   $ 281,000